Successful treatment of PR3-ANCA-positive interstitial pneumonia with a moderate dose of glucocorticoid and rituximab
Modern Rheumatology Case Reports · 2023
DOI: 10.1093/mrcr/rxad024 ↗Kurz gefasst
Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2023. Verfasst von Misako Higashida-Konishi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Cysts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Antineutrophil cytoplasmic antibody (ANCA)–positive interstitial pneumonia (IP) is reported as IP that is ANCA-positive and does not involve organ damage associated with vasculitis other than the lungs. While the combination of glucocorticoid and rituximab is effective in ANCA-associated vasculitis, the treatment strategy for ANCA-positive IP has not been established. Here, we report the first case of successful treatment of proteinase 3 (PR3)-ANCA-positive IP with a moderate dose of glucocorticoid and rituximab. The patient was an 80-year-old male who presented with subacute dry cough and dyspnoea. Blood tests revealed elevated levels of C-reactive protein, Krebs von den Lungen 6 (KL-6), and PR3-ANCA. Chest computed tomography (CT) showed interstitial shadows and infiltrates around honeycomb cysts. 18F-fluorodeoxyglucose (FDG) positron emission tomography CT revealed an uptake of FDG in the IP area. After starting treatment with a moderate dose of prednisolone and rituximab, the patient’s clinical symptoms disappeared, C-reactive protein and KL-6 turned to be normal, and infiltrates around the cysts of honeycomb lungs disappeared. Prednisolone was gradually decreased to 2 mg, and no relapse or adverse events were observed during the course of treatment. Our case suggests that early treatment with a moderate dose of glucocorticoid and rituximab is effective for PR3-ANCA-positive IP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
ORCID-Profile: Mitsuhiro Akiyama
Zitieren
APA
Higashida-Konishi, M., Akiyama, M., Hama, S., Oshige, T., Izumi, K., Oshima, H., & Okano, Y. (2023). Successful treatment of PR3-ANCA-positive interstitial pneumonia with a moderate dose of glucocorticoid and rituximab. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxad024
Vancouver
Higashida-Konishi M, Akiyama M, Hama S, Oshige T, Izumi K, Oshima H, et al. Successful treatment of PR3-ANCA-positive interstitial pneumonia with a moderate dose of glucocorticoid and rituximab. Modern Rheumatology Case Reports. 2023. doi:10.1093/mrcr/rxad024
BibTeX
@article{HigashidaKonishi2023,
author = {Higashida-Konishi, Misako and Akiyama, Mitsuhiro and Hama, Satoshi and Oshige, Tatsuhiro and Izumi, Keisuke and Oshima, Hisaji and Okano, Yutaka},
title = {Successful treatment of PR3-ANCA-positive interstitial pneumonia with a moderate dose of glucocorticoid and rituximab},
journal = {Modern Rheumatology Case Reports},
year = {2023},
doi = {10.1093/mrcr/rxad024}
}
EUVIMED